<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01057407</url>
  </required_header>
  <id_info>
    <org_study_id>1585-CL-0003</org_study_id>
    <nct_id>NCT01057407</nct_id>
  </id_info>
  <brief_title>A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis</brief_title>
  <official_title>A Phase 3, Multicenter, Open-label, Sevelamer Hydrochloride-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-labeled study to examine the non-inferiority of ASP1585 to
      sevelamer hydrochloride in chronic kidney disease patients with hyperphosphatemia on
      hemodialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum phosphorus level at the end of treatment</measure>
    <time_frame>After 12-week or at the treatment discontinuation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum phosphorus level</measure>
    <time_frame>After 12-week or at the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-course changes in serum phosphorus levels</measure>
    <time_frame>During Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum Ca x P</measure>
    <time_frame>During treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in intact PTH levels</measure>
    <time_frame>During Treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Renal Dialysis</condition>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>ASP group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevelamer group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1585</intervention_name>
    <description>oral</description>
    <arm_group_label>ASP group</arm_group_label>
    <other_name>ILY101</other_name>
    <other_name>AMG223</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer hydrochloride</intervention_name>
    <description>oral</description>
    <arm_group_label>Sevelamer group</arm_group_label>
    <other_name>Renagel</other_name>
    <other_name>phosbloc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic kidney disease patients on hemodialysis

          -  Hyperphosphatemia

          -  Patients on a phosphate binder or phosphate lowering drug for 28 days or longer, and
             that, those for whom the dose has not been changed within 28 days

          -  Written informed consent

        Exclusion Criteria:

          -  Patients with gastrointestinal surgery or enterectomy

          -  Patients with severe cardiac diseases

          -  Patients with severe constipation or diarrhea

          -  Patients with a history or complication of malignant tumors

          -  Patients with uncontrolled hypertension

          -  Patients treated with parathyroid intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyusyu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrSearch.jsp</url>
    <description>Link to Results on JAPIC - enter 150708 in the JapicCTI-RNo. field (Japanese record)</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2010</study_first_submitted>
  <study_first_submitted_qc>January 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2010</study_first_posted>
  <last_update_submitted>April 30, 2015</last_update_submitted>
  <last_update_submitted_qc>April 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperphosphatemia</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>CKD</keyword>
  <keyword>ASP1585</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

